SEC Form 4 · accession 0001209191-18-041857
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kyle Lefkoff
Director
Period of report
Jul 6, 2018
Accepted (ET)
Jul 6, 2018 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2018 | M | 25,000 | $5.13 | A | 42,720 | D | |
| Common Stock | Jul 6, 2018 | M | 25,000 | $5.95 | A | 67,720 | D | |
| Common StockF1 | Jul 6, 2018 | S | 50,000 | $17.45 | D | 17,720 | D | |
| Common StockF2 | holding | — | — | — | 45,000 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $5.13 | Jul 6, 2018 | M | 25,000 | D | Oct 29, 2015 | Oct 29, 2024 | Common Stock | 25,000 | 0 | D |
| Stock Option (Right to Buy) | $5.95 | Jul 6, 2018 | M | 25,000 | D | Oct 27, 2016 | Oct 27, 2025 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The price reported for these shares is the weighted average sale price of transactions made at prices from $17.45 to $17.461. Details of actual prices for shares sold are available from the Issuer upon request.
- F2Comprised of 30,000 shares of common stock in trust for the benefit of Mr. Lefkoff's minor children and 15,000 shares of common stock held by BV Partners III Profit Sharing account for the benefit of Mr. Lefkoff.